384 related articles for article (PubMed ID: 10487539)
21. The site of action of pantoprazole in the gastric H+/K(+)-ATPase.
Shin JM; Besancon M; Simon A; Sachs G
Biochim Biophys Acta; 1993 Jun; 1148(2):223-33. PubMed ID: 8389196
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
Andersson T
Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
[TBL] [Abstract][Full Text] [Related]
23. BY 1023/SK&F 96022 INN pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions.
Kromer W; Postius S; Riedel R; Simon WA; Hanauer G; Brand U; Gönne S; Parsons ME
J Pharmacol Exp Ther; 1990 Jul; 254(1):129-35. PubMed ID: 2164086
[TBL] [Abstract][Full Text] [Related]
24. Specific proton pump inhibitors E3810 and lansoprazole affect the recovery process of gastric secretion in rats differently.
Tomiyama Y; Morii M; Takeguchi N
Biochem Pharmacol; 1994 Nov; 48(11):2049-55. PubMed ID: 7802694
[TBL] [Abstract][Full Text] [Related]
25. Biochemical and pharmacological properties of a newly synthesized proton pump (H+/K(+)-ATPase) inhibitor, TY-11345 in experimental animals.
Yamaguchi T; Aihara K; Yamada S; Narita S; Kogi K
Jpn J Pharmacol; 1993 Aug; 62(4):363-71. PubMed ID: 8230863
[TBL] [Abstract][Full Text] [Related]
26. [Inhibitory action of E3810 on H+,K(+)-ATPase and gastric acid secretion in vitro].
Fujisaki H; Oketani K; Shibata H; Murakami M; Fujimoto M; Wakabayashi T; Yamatsu I; Takeguchi N
Nihon Yakurigaku Zasshi; 1993 Dec; 102(6):389-97. PubMed ID: 8282270
[TBL] [Abstract][Full Text] [Related]
27. Proton pump activation in stimulated parietal cells is regulated by gastric acid secretory capacity: a human study.
Metz DC; Ferron GM; Paul J; Turner MB; Soffer E; Pisegna JR; Bochenek WJ
J Clin Pharmacol; 2002 May; 42(5):512-9. PubMed ID: 12017345
[TBL] [Abstract][Full Text] [Related]
28. Biochemical and pharmacological characteristics of 3-butyryl-8-methoxy-4-[(2-thiophenyl)amino]quinoline, a new proton-pump inhibitor, in rabbit gastric microsomes and in rats.
Kim KB; Chang MS; Chung YK; Sohn SK; Kim SG; Choi WS
J Pharm Pharmacol; 1998 May; 50(5):521-9. PubMed ID: 9643446
[TBL] [Abstract][Full Text] [Related]
29. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates.
Kromer W; Krüger U; Huber R; Hartmann M; Steinijans VW
Pharmacology; 1998 Feb; 56(2):57-70. PubMed ID: 9494064
[TBL] [Abstract][Full Text] [Related]
30. Sulfide and sulfoxide derivatives of substituted benzimidazoles inhibit acid formation in isolated gastric glands by different mechanisms.
Fryklund J; Wallmark B
J Pharmacol Exp Ther; 1986 Jan; 236(1):248-53. PubMed ID: 3001289
[TBL] [Abstract][Full Text] [Related]
31. Continuing development of acid pump inhibitors: site of action of pantoprazole.
Shin JM; Besancon M; Prinz C; Simon A; Sachs G
Aliment Pharmacol Ther; 1994; 8 Suppl 1():11-23. PubMed ID: 7514042
[TBL] [Abstract][Full Text] [Related]
32. (H+,K+)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 4. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity. The selection of pantoprazole as a clinical candidate.
Kohl B; Sturm E; Senn-Bilfinger J; Simon WA; Krüger U; Schaefer H; Rainer G; Figala V; Klemm K
J Med Chem; 1992 Mar; 35(6):1049-57. PubMed ID: 1313110
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of protection by pantoprazole against NSAID-induced gastric mucosal damage.
Fornai M; Natale G; Colucci R; Tuccori M; Carazzina G; Antonioli L; Baldi S; Lubrano V; Abramo A; Blandizzi C; Del Tacca M
Naunyn Schmiedebergs Arch Pharmacol; 2005 Jul; 372(1):79-87. PubMed ID: 16080005
[TBL] [Abstract][Full Text] [Related]
34. Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion.
Dammann HG; Burkhardt F
Eur J Gastroenterol Hepatol; 1999 Nov; 11(11):1277-82. PubMed ID: 10563540
[TBL] [Abstract][Full Text] [Related]
35. Reversible and potent uncoupling of hog gastric (H(+)+K(+))-ATPase by prodigiosins.
Matsuya H; Okamoto M; Ochi T; Nishikawa A; Shimizu S; Kataoka T; Nagai K; Wasserman HH; Ohkuma S
Biochem Pharmacol; 2000 Dec; 60(12):1855-63. PubMed ID: 11108801
[TBL] [Abstract][Full Text] [Related]
36. Effects of pantoprazole on xenobiotic metabolizing enzymes in rat liver microsomes: a comparison with other proton pump inhibitors.
Masubuchi N; Hakusui H; Okazaki O
Drug Metab Dispos; 1997 May; 25(5):584-9. PubMed ID: 9152597
[TBL] [Abstract][Full Text] [Related]
37. Possible mechanism for the inhibition of gastric (H+ + K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749.
Nagaya H; Satoh H; Kubo K; Maki Y
J Pharmacol Exp Ther; 1989 Feb; 248(2):799-805. PubMed ID: 2537417
[TBL] [Abstract][Full Text] [Related]
38. Synthesis or rupture: duration of acid inhibition by proton pump inhibitors.
Sachs G; Shin JM; Pratha V; Hogan D
Drugs Today (Barc); 2003 Mar; 39 Suppl A():11-4. PubMed ID: 12712216
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.
Andersson T; Holmberg J; Röhss K; Walan A
Br J Clin Pharmacol; 1998 Apr; 45(4):369-75. PubMed ID: 9578184
[TBL] [Abstract][Full Text] [Related]
40. Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole.
Huber R; Kohl B; Sachs G; Senn-Bilfinger J; Simon WA; Sturm E
Aliment Pharmacol Ther; 1995 Aug; 9(4):363-78. PubMed ID: 8527612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
